Michael Schmitz
Stock Analyst at Guggenheim
(2.05)
# 3,231
Out of 4,915 analysts
7
Total ratings
66.67%
Success rate
1.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Buy | $45 | $36.54 | +23.15% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $36.80 | +122.83% | 2 | Oct 28, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $66.00 | +68.18% | 2 | Oct 1, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $7.29 | +448.70% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.08 | - | 1 | Jan 3, 2023 |
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $36.54
Upside: +23.15%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $36.80
Upside: +122.83%
Merus
Oct 1, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $66.00
Upside: +68.18%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $7.29
Upside: +448.70%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -